{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:20:09Z","timestamp":1793053209127,"version":"4.5.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Metformin has shown its effectiveness in reducing body mass index (BMI) in obese children and adolescents, but relevant evidence for improving insulin resistance in overweight or obese children and adolescents is inconclusive.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>This study aimed to assess whether metformin could effectively and safely improve homeostasis model assessment insulin resistance index (HOMA-IR) and other related laboratory indicators including fasting glucose, fasting insulin, high-density lipoprotein cholesterol (HDL-C), and low density lipoprotein-cholesterol (LDL-C).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Searches were carried out in PubMed, CENTRAL, Web of Science, EMBASE, CBM, Chinese National Knowledge Infrastructure (CNKI), and WanFang from their inception until March 2018. Randomized controlled trials (RCTs) comparing metformin alone with placebo in overweight or obese children and adolescents were included. The Cochrane risk of bias tool was applied to assess the methodological quality of every study and Meta-analysis was carried out with a random effects model or a fixed effects model. Publication bias was evaluated by the Begg and Egger tests.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 11 trials with a total of 865 participants met the inclusion criteria. Participants were between 4 and 18 years old. The time span of these studies ranged from 2001 to 2017. The daily dose of metformin was from 1000\u200amg to 2000\u200amg and the duration of intervention was 8 weeks to 18 months. Compared with placebo, metformin with lifestyle intervention reduced the level of LDL-C (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a008, MD = - 4.29, 95% confidence interval [CI]: -7.45, -1.12). However, there was no obvious differences in improving insulin resistance, fasting glucose, and HDL-C.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Metformin may improve the level of LDL-C, but it has no significant effect on insulin resistance. The use of metformin may be a new approach to lipid metabolism management in overweight or obese children and adolescents.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Registration number:<\/jats:title>\n            <jats:p>CRD42018092059.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000014249","type":"journal-article","created":{"date-parts":[[2019,1,25]],"date-time":"2019-01-25T07:15:32Z","timestamp":1548400532000},"page":"e14249","source":"Crossref","is-referenced-by-count":24,"title":["The effects of metformin on insulin resistance in overweight or obese children and adolescents: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1097","volume":"98","author":[{"given":"Juan","family":"Sun","sequence":"first","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Nantong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[{"name":"Nantong University, Nantong City, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Nantong University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"He","sequence":"additional","affiliation":[{"name":"Department of Nursing, Affiliated Hospital of Nantong University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20230914","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-4285","article-title":"Metformin for obesity in prepubertal and pubertal children: a randomized controlled trial","volume":"140","author":"Pastor-Villaescusa","year":"2017","journal-title":"Pediatrics"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/ijo.2016.69","article-title":"Pediatric obesity pharmacotherapy: current state of the field, review of the literature and clinical trial considerations","volume":"40","author":"Kelly","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1463-1326.2010.01286.x","article-title":"Managing childhood obesity: when lifestyle change is not enough","volume":"12","author":"Hearnshaw","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/0272989X05282643","article-title":"The interpretation of random-effects meta-analysis in decision models","volume":"25","author":"Ades","year":"2005","journal-title":"Med Decis Making"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1053\/meta.2001.28078","article-title":"Beneficial effects of metformin in normoglycemic morbidly obese adolescents","volume":"50","author":"Kay","year":"2001","journal-title":"Metabolism"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1515\/JPEM.2008.21.4.339","article-title":"Use of metformin in obese adolescents with hyperinsulinemia: a 6-month, randomized, double-blind, placebo-controlled clinical trial","volume":"21","author":"Atabek","year":"2008","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1399-5448.2008.00434.x","article-title":"Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance","volume":"9","author":"Burgert","year":"2008","journal-title":"Pediatr Diabetes"},{"key":"R13-20230914","first-page":"116","article-title":"Metformin extended release treatment of adolescent obesity: a 48-week randomized, double-blind, placebo-controlled trial with 48-week follow-up","volume":"164","author":"Wilson","year":"2010","journal-title":"Arch Pediatr Adolesc Med"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2337\/db10-1185","article-title":"Effects of metformin on body weight and body composition in obese insulin-resistant children: a randomized clinical trial","volume":"60","author":"Yanovski","year":"2011","journal-title":"Diabetes"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1515\/jpem-2011-0469","article-title":"The effects of metformin on inflammatory mediators in obese adolescents with insulin resistance: controlled randomized clinical trial","volume":"25","author":"Evia-Viscarra","year":"2012","journal-title":"J Pediatr Endocrinol Metab"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1210\/jc.2012-2710","article-title":"Metformin in obese children and adolescents: the MOCA trial","volume":"98","author":"Kendall","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.metabol.2012.02.003","article-title":"Metformin decreases plasma resistin concentrations in pediatric patients with impaired glucose tolerance: a placebo-controlled randomized clinical trial","volume":"61","author":"Gomez-Diaz","year":"2012","journal-title":"Metabolism"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"e228","DOI":"10.1038\/nutd.2016.37","article-title":"Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial","volume":"6","author":"van der Aa","year":"2016","journal-title":"Nutr Diabetes"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1210\/jc.2016-2701","article-title":"Effects of conjugated linoleic acid and metformin on insulin sensitivity in obese children: randomized clinical trial","volume":"102","author":"Garibay-Nieto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.disamonth.2017.12.001","article-title":"Pediatric obesity: current concepts","volume":"64","author":"Greydanus","year":"2018","journal-title":"Dis Mon"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"A18","DOI":"10.1016\/j.clinthera.2012.12.014","article-title":"Childhood obesity: a review of increased risk for physical and psychological comorbidities","volume":"35","author":"Pulgaron","year":"2013","journal-title":"Clin Ther"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41574-018-0002-8","article-title":"Treatment of adolescent obesity","volume":"14","author":"Steinbeck","year":"2018","journal-title":"Nat Rev Endocrinol"},{"key":"R23-20230914","first-page":"Cd012436","article-title":"Drug interventions for the treatment of obesity in children and adolescents","volume":"11","author":"Mead","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1177\/1060028014557859","article-title":"Pharmacological management of obesity in pediatric patients","volume":"49","author":"Boland","year":"2015","journal-title":"Ann Pharmacother"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201901250-00066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T18:30:56Z","timestamp":1694716256000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201901250-00066"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014249","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}